Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics Q1 revenue rises 17% to $794.4 million; diluted EPS $6.63

Positive Impact 3 of 5 earnings Written later

United Therapeutics reported first quarter 2025 results for the quarter ended March 31, 2025, with total revenues up 17% year over year to $794.4 million. Net income rose 5% to $322.2 million, and diluted earnings per share rose 7% to $6.63, though research and development expense grew 43% to $149.0 million.

Key points

  • Total Tyvaso revenues rose 25% to $466.3 million, led by Tyvaso DPI at $302.5 million, up 33%.
  • Net income was $322.2 million versus $306.6 million a year earlier; diluted EPS was $6.63 versus $6.17.
  • Research and development expense rose to $149.0 million from $104.1 million, including a $30.0 million increase in milestone payments for drug delivery device technologies.
  • The filing contains no revenue or earnings guidance; the company said it would host a webcast on April 30, 2025 at 9:00 a.m. Eastern Time.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECApr 30, 2025, 6:33 AM ET
Accession number0001082554-25-000024

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.